- Home
- PWP vs KNSA Comparison
PWP vs KNSA Comparison
Compare PWP & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWP
- KNSA
- Stock Information
- Founded
- PWP 2006
- KNSA 2015
- Country
- PWP United States
- KNSA United Kingdom
- Employees
- PWP N/A
- KNSA N/A
- Industry
- PWP Finance: Consumer Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- PWP Finance
- KNSA Health Care
- Exchange
- PWP Nasdaq
- KNSA Nasdaq
- Market Cap
- PWP 1.4B
- KNSA 1.6B
- IPO Year
- PWP N/A
- KNSA 2018
- Fundamental
- Price
- PWP $18.49
- KNSA $21.77
- Analyst Decision
- PWP Hold
- KNSA Strong Buy
- Analyst Count
- PWP 3
- KNSA 6
- Target Price
- PWP $25.00
- KNSA $37.17
- AVG Volume (30 Days)
- PWP 764.6K
- KNSA 572.9K
- Earning Date
- PWP 05-02-2025
- KNSA 04-22-2025
- Dividend Yield
- PWP 1.52%
- KNSA N/A
- EPS Growth
- PWP N/A
- KNSA N/A
- EPS
- PWP N/A
- KNSA N/A
- Revenue
- PWP $878,039,000.00
- KNSA $423,239,000.00
- Revenue This Year
- PWP $18.45
- KNSA $37.21
- Revenue Next Year
- PWP $12.02
- KNSA $1.38
- P/E Ratio
- PWP N/A
- KNSA N/A
- Revenue Growth
- PWP 35.36
- KNSA 56.60
- 52 Week Low
- PWP $11.68
- KNSA $16.56
- 52 Week High
- PWP $27.03
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- PWP 34.48
- KNSA 47.67
- Support Level
- PWP $17.68
- KNSA $22.62
- Resistance Level
- PWP $20.81
- KNSA $23.42
- Average True Range (ATR)
- PWP 0.86
- KNSA 0.70
- MACD
- PWP 0.02
- KNSA -0.18
- Stochastic Oscillator
- PWP 25.88
- KNSA 3.05
About PWP Perella Weinberg Partners
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.